A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
Moshe C. Ornstein, Laura S. Wood, Brian P. Hobbs, Kimberly D. Allman, Allison Martin, Michael Bevan, Timothy D. Gilligan, Jorge A. Garcia, Brian I. Rini
Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 127; DOI: 10.1186/s40425-019-0615-z